Ultragenyx Pharma (RARE) Misses Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Ultragenyx Pharma (RARE) Misses Q4 EPS by 28c
February 25, 2016 4:06 PM EST
NOVATO, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the fourth quarter and full-year ended December 31, 2015.
2015 was a transformative year for Ultragenyx in which we advanced our entire product portfolio providing new possibilities for the treatment of rare disease patients, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. In 2016, we expect to have many clinical, regulatory and business development updates as we... More
